
FDA news recap in urology for Q2 2025
The specialty of urology, following an eventful first quarter, had a busy Q2 with a flurry of FDA approvals (and 1 notable non-approval) ranging from benign prostatic hyperplasia (BPH) to urge incontinence to bladder cancer and prostate cancer. Q2 also saw …